Key Highlights
- Third-quarter Revenue was USD 1.2 million, against USD 1.2 million a year earlier.
- Cash was approximately USD 18 million at the end of September 2026.
- The company closed a USD 15 million Series C convertible preferred offering on October 21.
- Management said Medicare is now paying for EsoGuard test claims.
Lucid Diagnostics (NASDAQ:LUCD) reported third-quarter 2026 revenue of USD 1.20 million, against an estimate of USD 1.63 million. Loss per share was USD 0.06, in line with the estimate of USD 0.06. The company is a commercial-stage diagnostics Business focused on esophageal precancer detection through its EsoGuard test and EsoCheck cell collection device.
On the call, management described the Medicare development as a seminal moment in its mission to end esophageal cancer. It said Medicare beneficiaries nationwide now have reimbursed access to EsoGuard, and that the company began submitting Medicare claims in September and began receiving payments shortly after.
Revenue, Costs and Reimbursement
Management said revenue of USD 1.2 million was essentially flat with the USD 1.2 million reported in the third quarter of last year, and down USD 1.5 million from the second quarter. The quarter's composition included USD 1.4 million of cost of revenue, USD 4.9 million of sales and marketing, USD 4.5 million of general and administrative expenses and USD 1 million of research and development.
Management pointed to the average insurance allowable amount for successful claims, which it put at USD 1,700 per test in the third quarter. It compared that with USD 1,420 in the second quarter and a year-to-date average of USD 1,600. The sales team sold 2,870 tests in the quarter, and the company delivered 517 direct contract tests. Medicare test Volume represented about 16% of the third-quarter mix, or about 450 tests.
Management said approximately 10% to 15% of the 50,000 EsoGuard tests performed to date have been on Medicare beneficiaries. It said approximately 50% of the 30 million patients in the at-risk population are of Medicare age. For denied claims, management gave a mix of roughly 21% deemed not medically necessary or investigational, 18% out of network, 17% from noncovered routine screening exams and 17% requiring additional documentation or prior authorization.
Balance Sheet and Financing
As of September 30, 2026, the filing states Working Capital of approximately USD 4.3 million, which includes the 2024 Convertible Notes classified as a current Liability of approximately USD 17.3 million. Cash was approximately USD 18.0 million. On the call, management said a USD 15 million Series C convertible preferred offering closed on October 21, bringing the pro forma cash position to approximately USD 33 million.
The filing says the company sold 15,000 shares of newly designated Series C Convertible Preferred Stock at a purchase price of USD 1,000 per share to certain accredited investors. On the call, management said the conversion price on the notes reset from USD 1 to 35.19 cents upon issuance of the Series C.
In the nine months ended September 30, 2026, the company sold 4,298,616 shares through its at-the-market Equity Facility for net proceeds of approximately USD 5.4 million, after payment of 3% commissions of approximately USD 0.2 million. On March 13, 2026, it issued 7,094,159 common shares, with a Fair Value of approximately USD 9.7 million at issuance, in satisfaction of the Series B Preferred Stock dividend. As of September 30, 2026, 22,304,671 shares of common stock remained in abeyance.
Operating Lease obligations were USD 1,187 thousand at September 30, 2026, against USD 1,820 thousand at December 31, 2025. Of the current total, USD 908 thousand is in current operating lease liabilities. A total of 242,284 shares were purchased under the Lucid employee stock purchase plan on March 31, 2026, for proceeds of approximately USD 210 thousand.
Commercial Priorities
Management said the commercial team transitioned its focus to access in the Medicare population after reimbursement was secured, using incentivized compensation plans and data-driven routing. It said a new Category 3 CPT code linked to an ICD-10 diagnosis code gives physicians a way to document follow-up endoscopy after a positive EsoGuard result. Management said that in the first month of the fourth quarter its team had already achieved nearly 70% of the third-quarter Medicare volume.






Please wait processing your request...